Key Highlights

  • Shares rose USD 0.0911, or 17.59%, to USD 0.6089 in pre-market trading on November 4, 2026.
  • No company announcement dated November 2 to November 4, 2026 could be found.
  • Cash stood at USD 3,609,442 on June 30, 2026, compared with USD 6,346,921 at December 31, 2025.
  • The second-quarter 2026 net loss was USD 1,208,534, and the filing raised substantial doubt about going concern.
  • A Phase 2a study of Ketamir-2 in chemotherapy-induced peripheral neuropathy advanced toward site initiation on September 17, 2026.

MIRA Pharmaceuticals Price Action Before the Open (up USD 0.0911, 17.59%)

MIRA Pharmaceuticals (NASDAQ:MIRA) gained USD 0.0911, or 17.59%, to USD 0.6089 in pre-market trading on November 4, 2026. That implies a Tuesday, November 3 close near USD 0.5178 (calculated from the quote figures).

No press release, regulatory filing or Earnings report from the company dated November 2 to November 4, 2026 could be found. Without a stated trigger, the likeliest drivers are momentum in low-priced biotech shares, a rebound after recent weakness and speculative positioning ahead of the open. These are possibilities, not confirmed causes.

Latest Company Updates

The most recent items on record are pipeline updates. A company press release dated October 22, 2026 reported that oral MIRA-55 reduced chronic inflammatory pain and swelling in a rat study, with effects described as comparable to a widely used anti-inflammatory at higher doses. The company said pain relief lasted 21 days and that it is working toward an investigational new drug filing in 2027.

On September 17, 2026, the company said its Phase 2a program for Ketamir-2 in chemotherapy-induced peripheral neuropathy had moved toward site initiation after the FDA reviewed the protocol. The protocol had been submitted for institutional review board review at a leading cancer research institution.

A company press release dated June 17, 2026 outlined a randomized, double-blind, placebo-controlled crossover design that tests 300 mg and 600 mg doses against placebo.

Company Background and Results

MIRA is a clinical-stage drug developer based in Miami, focused on oral candidates for neurologic, neuropsychiatric and metabolic conditions. The company says the DEA has confirmed that its oral NMDA receptor modulator, Ketamir-2, is non-scheduled. The Phase 1 program enrolled 56 healthy volunteers, and the company reported no serious adverse events or dose-limiting toxicities.

Ketamir-2 has not been approved for any use, and its safety and efficacy remain unestablished.

The second-quarter 2026 Form 10-Q reported operating expenses of USD 1,156,119, consisting of USD 705,789 in Research and Development and USD 450,330 in general and administrative costs.

Balance Sheet and Risk Factors

Cash dropped to USD 3,609,442 on June 30, 2026 from USD 6,346,921 at December 31, 2025, a decline of about USD 2.7 million (calculated). Management said cash is insufficient to fund operations for at least 12 months, and the filing stated that these factors raise substantial doubt about the company's ability to continue as a going concern. Shares outstanding were 42,022,087 as of August 10, 2026.

The company holds an at-the-market agreement permitting aggregate sales of up to USD 75 million, and it did not draw on it in the first half of 2026. Any future use would add shares and could dilute holders. As a stock under USD 5, MIRA can swing sharply, trade with limited Liquidity and carry dilution risk.

Key Items to Monitor

Investors will want a company statement explaining the move, plus the third-quarter 2026 Form 10-Q, which will refresh the cash figure and Going Concern language. Progress toward site initiation in the Ketamir-2 Phase 2a study and any financing disclosure will also count. Pre-market gains of this size can fade or reverse once the regular session starts.